ClinicalTrials.gg
RecruitingNCT06638502Updated Sep 14, 2026

Safety of HRX215 in Patients After Minor and Major Liver Resection

A Phase 1/2 interventional study of HRX215 capsules and Placebo capsules in Liver Resection and Colorectal Carcinoma Liver Metastases, sponsored by HepaRegeniX GmbH. Recruiting at 14 sites in 5 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-14.

Sponsored by HepaRegeniX GmbH · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 2,342 studies in Colorectal Neoplasms with a site in United States — 415 open to participants now, 629 under way, 30 of them phase 3. Colorectal Neoplasms · United States.

Planned enrollment
871st of 1,934
80 · median 64
Started
2025
with 143 others
Phase 1/2
267 of 2,342
67 open now
Primary completion
2027-07
later than 284 of 627 live
Registered
2,079th of 2,342
by date

Among the 2,342 studies in Colorectal Neoplasms with a site in United States, this one is the 871st largest by planned enrollment of the 1,934 interventional ones that give a count, is one of 144 that started in 2025, is one of 267 in phase 1/2, reaches primary completion later than 284 of the 627 other live ones, and was the 2,079th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

415 of the 2,342 studies in Colorectal Neoplasms with a site in United States are open now. Recruiting first, the newest first:

410 more — sign in →

All 415 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,342 studies in Colorectal Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if HRX215 is safe, tolerable and active in adults who have undergone liver resection due to colorectal carcinoma metastases.

The objectives are:

  1. to learn about the safety and tolerability of HRX215
  2. to learn about how the body absorbs, distributes, and gets rid of HRX215.
  3. to learn about clinical activity of HRX215

Researchers will compare HRX215 to a placebo (a look-alike substance that contains no drug) to investigate safety, tolerability and clinical activity in participants taking HRX215.

Read the detailed description

The study is designed to evaluate primarily the safety of HRX215, first after minor liver resection and subsequently in participants after major liver resection. Participants undergoing major liver resection will start treatment shortly before liver resection surgery and will receive 28 days of treatment with HRX215 or placebo twice daily with follow up visits at 3 and 6 months.

Participants will take HRX215 or a placebo twice a day for 28 days. Daily visits for the first 7 days of treatment for checkups and tests which may either be in the hospital or outpatient after 3 days. Clinic visits every two weeks for the next two visits. Additional clinic visits 3 months and 6 months after the start of treatment.

The pharmacokinetics will be compared with the results of the phase I studies in healthy subjects.

Secondary objectives will include evaluation of liver volume and liver volume increase postoperatively.

03

Conditions studied

  • Liver Resection
  • Colorectal Carcinoma Liver Metastases
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with liver originating from colon carcinoma planned for R0-intended hepatectomy for colorectal liver metastases
  • Part 1 only: stable participants within 1-3 days after minor liver resection, normal non-tumor liver parenchyma
  • Part 2 and 3 only: Major liver resection.
  • Low estimated risk for post-hepatectomy liver failure PHLF

Further inclusion criteria apply

Exclusion criteria

Exclusion Criteria:

  • Liver Cirrhosis
  • Preoperative presence of clinical ascites
  • Any other hepatobiliary cancer
  • >35 kg/m2
  • ASA Score >4
  • Peritoneal carcinomatosis

Further exclusion criteria apply

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Active treatment minor hepatic resection

    Pilot 1: 5 participants will receive HRX215 starting within 1-3 days after minor liver resection for colorectal liver metastases.

    Drug: HRX215 capsules

  • Experimental
    Active treatment major hepatic resection

    Pilot 2: 10 participants will receive HRX215 starting treatment prior to major liver resection for colorectal liver metastases.

    Drug: HRX215 capsules

  • Placebo comparator
    Major hepatic resection (Randomized part control arm)

    32 participants will receive placebo starting administration prior to major liver resection for colorectal liver metastases

    Drug: Placebo capsules

  • Experimental
    Major hepatic resection (Randomized part)

    32 participants will receive HRX215 starting administration prior to major liver resection for colorectal liver metastases.

    Drug: HRX215 capsules

Interventions

  • DrugHRX215 capsules

    HRX215 250 mg orally twice daily for a total treatment duration of 28 days

  • DrugPlacebo capsules

    placebo matching appearance of HRX215, orally twice daily for a total treatment duration of 28 days

06

What researchers measure

Primary outcomes

  1. Adverse Events (AEs) observed

    Incidence, severity, and relatedness of AEs/SAEs. Changes in vital signs and physical examination findings. Clinical laboratory investigation.

    Time frame: 6 months

  2. HRX215 plasma levels

    Levels of drug (HRX215) at selected time intervals after drug administration

    Time frame: 28 days

Secondary outcomes

  1. Efficacy (major liver resection)

    Liver volume and increase in liver volume at postoperative day 7 vs. postoperative day 1

    Time frame: 7 days

07

Study locations

13 of 14 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Jul 2027, 26 months after the start.

Of 159 industry-sponsored phase 1/2 interventional studies under Colorectal Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 82. This study's planned 26 months is below that.

Counting every sponsor, half of 261 studies reached it within 59 months; a quarter within 36 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2024
First posted
Oct 15, 2024
StartActual
May 6, 2025
Primary completionEst.
Jul 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Sep 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06638502
Lead sponsor
HepaRegeniX GmbH
Responsible party
Sponsor
First posted
Oct 15, 2024
Start date
May 6, 2025
Primary completion
Jul 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Sep 14, 2026

Study contacts

Wolfgang Albrecht, PhD NC
Contact
info@heparegenix.com
+49 7071 7912809
Linda Greenbaum, MD
Contact
l.greenbaum@heparegenix.com
484-343-2409
Linda E Greenbaum, MD
study director · HepaRegeniX GmbH
Patrick Starlinger, MD, PhD
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion